New clinical trials detail the failure of two COVID-19 treatments—a combination of interferon beta-1a and remdesivir and the drug colchicine—to reduce death by 28 days, length of hospital stay, or risk of requiring invasive mechanical ventilation or dying in hospitalized adults.Both trials were published yesterday in The Lancet Respiratory Medicine.More adverse events with interferon beta-1aIn a phase 3 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases, a team led by a University of Nebraska researcher randomly assigned 969 COVID-19 patients admitted to 63 hospitals in five countries (Japan, Mexico, Singapore, South Korea, and the United States) in a 1:1 ratio to receive either interferon beta-1a plus